Lipid emulsion reduces subacute toxicity of amphotericin B: A histopathological study

Experimental and Toxicologic Pathology

Volumn 52, Issue 2, 2000, Pages 169-175

  Souza, Liliete Canes ^a   Saldiva, Paulo Hilário Nascimento ^a   Campa, Ana ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Amphotericin B; Lipid emulsion; Toxicity

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; IRON; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG FORMULATION; DRUG TOXICITY; HEART; HISTOPATHOLOGY; LIVER TOXICITY; LUNG TOXICITY; MALE; MORPHOMETRICS; NEPHROTOXICITY; NONHUMAN; RAT; SPLEEN; STEREOLOGY;

ANIMALIA;

EID: 0343238502     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0940-2993(00)80115-3     Document Type: Article

References (34)

1. ABU-SALA KM, SEDRANI SH, TOBIA AS, et al.: Influence of amphotericin B on the transport of phosphate, sulphate and potassium across the human erythrocyte membrane. Acta Haematol 1988; 79: 77-80.
2. BHATHENA DB, BULLOCK WE, NUTTALL CE, LUKE RG: The effects of amphotericin B therapy on the intrarenal vasculature and renal tubules in man. Clin Nephrol 1978; 9: 103-110.
3. BOLARD J: How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochim Biophys Acta 1986; 864: 257-304.
4. BOSSCHE HV, WILLEMSENS G, MARICHAL P: Anti-candida drugs - the biochemical basis for their activity. Crit Rev Microbiol 1987; 15: 57-72.
5. BRAJTBURG J, ELBERG S, KOBAYASHI GS, MEDOFF G: Effects of ascorbic acid on the antifungal action of amphotericin B. J. Antimicrob Chemother 1989; 24: 333-337.
6. BRAJTBURG J, ELBERG S, SCHWARTZ DR, et al.: Involvement of oxidative damage in erythrocyte lysis induced by amphotericin B. Antimicrob Agents Chemother 1985; 29: 172-176.
7. BRAJTBURG J, MEDOFF G, KOBAYASHI GS, et al.: Permeabilizing and haemolytic action of large and small polyene antibiotics on human erythrocytes. Antimicrob Agents Chemother 1980; 18: 585-592.
8. BROOKS DP, MITCHELL MP, SHORT BG, et al.: Attenuation of amphotericin B nephrotoxicity in the dog by the fenoldopam prodrug. SK&F R-105058. J Pharmacol Experim Therap 1991; 257: 1243-1247.
9. BULLOCK WE, LUKE RG, NUTTALL CE, BHATHENA D: Can manitol reduce amphotericin B nephrotoxicity? Antimicrob Agents Chemother 1976; 10: 555-563.
10. CHAVANET P, CHARLIER N, BRENET A, et al.: Emulsion of amphotericin B in Intralipid 20%: in vitro and in vivo efficacy. Pathol Biol 1992; 40: 507-512.
11. CHOPRA R, BLAIR S, STRANG J, et al.: Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients. J Antimicrob Chemother 1991; 28: 93-104.
12. DAVIS SS, WASHINGTON C, WEST P, et al.: Lipid emulsions as drug delivery systems. Ann N Y Acad Sci 1987; 507: 75-88.
13. FIELDING RM, SINGER AW, WANG LH, et al.: Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrobial Agents Chemother 1992; 36: 299-307.
14. GUNDERSEN HJG, BENDTSEN TF, KORBO L, et al.: Some new simple and efficient stereological methods and their use in pathological research and diagnosis. Acta Pathol Microbiol Immunol Scand 1988; 96: 379-394.
15. HARDIE WD, WHEELER AP, WRIGHT PW: Effect of cyclooxygenase inhibition of amphotericin B-induced lung injury in awake sheep. J Infect Dis 1992; 166: 134-138.
16. HOOVER DM, GARDNER JB, TIMMERMANN TL, et al.: Comparison of in vitro and in vivo models to assess venous irritation of parenteral antibiotics. Fundam Appl Toxicol 1990; 14: 589-597.
17. JANOFF AS, BONI LT, POPESCU MC, et al.: Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci USA 1988; 85: 6122-6126.
18. KAMP HH, WIRTZ KWA, BAER PR: Specificity of the phosphatidylcholine exchange protein from bovine liver. Biochemistry 1977; 16: 1310-1316.
19. LEE JW, AMANTEA MA, FRANCIS PA: Pharmacokinetics and safety of a unilammelar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Chemother 1994; 38: 713-8.
20. LOPEZ-BERESTEIN G, BODEY GP, FRANKEL LS, MEHTA K: Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol 1987; 5: 310-317.
21. MARZZULLO L, SOUZA LC, CAMPA A: Effect of amphotericin B associated with a lipid emulsion on the oxidative burst of human polymorphonuclear leukocytes. Gen Pharmacol 1997; 28: 203-207.
22. MCDONNELL TJ, CHANG SW, ESTCOTT JY, VOELKEL NF: Role of oxidants, eicosanoids, and neutrophils in amphotericin B lung injury in rats. J Appl Physiol 1988; 65: 2195-2206.
23. PALLER MS: Drug-induced nephropathies. Med Clin North Am 1990; 74: 909-917.
24. PERFECT JR, WRIGHT KA: Amphotericin B lipid complex in the treatment of experimental cryptococca meningitis and disseminated candidosis. J Antimicrob Chemother 1994; 33: 73-81.
25. PROFFITT RT, SATORIUS A, CHIANG S, et al.: Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother 1991; 28: 49-61.
26. REDGRAVE TG, MARANHÃO RC: Metabolism of protein-free lipid emulsion models of chylomicrons in rats. Biochim Biophys Acta 1985: 835: 104-112.
27. REYNOLDS ES, TOMKIEWICZ ZM, DAMMIN GJ: The renal lesions related to amphotericin B treatment for coccidioidomycosis. Med Clin North Amer 1963; 47: 1149-1154.
28. SINGLETON WS, GRAY MS, BROWN ML, WHITE JL: Chromatographically homogenous lecithin from egg phospholipids. J Am Oil Chem Soc 1965; 42: 53-56.
29. SOUZA LC, CAMPA A: Pharmacological parameters of endovenous administered AB in rats: comparison of conventional AB formulation with AB associated with a triglyceride-rich emulsion. J Antimicrob Chemother 1999; 44: 77-84.
30. SOUZA LC, MARANHÃO RC, SCHREIER S, CAMPA A: In-vitro and in-vivo studies of the decrease of amphotericin B toxicity upon association with a triglyceride-rich emulsion. J Antimicrob Chemother 1993; 32: 123-132.
31. WERTLAKE PT, BUTLER WT, HILL HGJ, UTZ JP: Nephrotoxic tubular damage and calcium deposition following amphotericin B therapy. Am J Pathol 1963; 43: 449-457.
32. nd ed. pp. 907, Tokyo: Mcgraw-Hill Kogakusha, 1971.
33. VAN ETTEN EWM, GROOT CH, BAKKER-WOUDENBERG IAJM: Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidiasis in immunocompetent and leucopenic mice. J Antimicrob Chemother 1995; 32: 723-739.
34. VAN ETTEN EWM, OTTE-LAMBILLION M, VAN VIANEN W, et al.: Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. J Antimicrob Chemother 1993; 35: 509-519.